Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

Zejula was first approved in 2017 as a monotherapy ... rates to platinum-based chemotherapy in the second-line advanced treatment setting, approximately 85% of patients will experience recurrence ...

In September, it also voluntarily withdrew Zejula’s fourth-line indication for the treatment advanced ovarian, fallopian tube, or primary peritoneal cancer with homologous recombination ...

Third quarter growth was driven by continued momentum from Experior add tab and Credelio Plus as well as the US and Brazil launch of ZEJULA late in September ... provide support on questions and ...

Targeted therapies including Lynparza (olaparib), Rubraca (rucaparib), Zejula (niraparib), and Talzenna (talazoparib) are all important new treatments for BRCA-positive breast cancers. The most recent ...

Though it’s the most common skin condition in the United States, determining the best acne treatment for your skin is still challenging. Acne treatments include prescription medications ...